Literature DB >> 33131314

Factors Associated With Failure to Achieve the Intensive Blood Pressure Target in the Systolic Blood Pressure Intervention Trial (SPRINT).

Katherine M Wang1, Margaret R Stedman1, Glenn M Chertow1, Tara I Chang1.   

Abstract

SPRINT (Systolic Blood Pressure Intervention Trial) found that randomization of nondiabetic participants at high cardiovascular risk to an intensive (systolic blood pressure [SBP] <120 mm Hg) versus standard (SBP <140 mm Hg) target resulted in 25% risk reduction in the first cardiovascular composite event (ie, cardiovascular death or nonfatal myocardial infarction, stroke, or hospitalization for heart failure) and a 27% risk reduction in all-cause mortality. In this post hoc analysis, we sought to determine the factors associated with failure to achieve the SBP target in 4678 SPRINT participants randomized to the intensive treatment group. Using a generalized estimating equation model, we assessed variables associated with failure to achieve the intensive SBP target as a repeated outcome collected during serial follow-up visits, including the occurrence of serious adverse events. In the multivariable model adjusted for baseline demographic, clinical, and laboratory variables, older age, higher SBP, underlying chronic kidney disease, higher number of antihypertensives, and moderate cognitive impairment at screening were associated with failure to achieve the intensive SBP target. Occurrence of a serious adverse event during the trial was associated with 20% higher odds of failure to achieve the SBP target. Participants of Hispanic ethnicity had 47% lower odds of failure to achieve the intensive SBP target relative to non-Hispanic Whites. Understanding barriers to achieving intensive SBP targets should allow clinicians to optimize management of hypertension in patients at high risk for cardiovascular disease.

Entities:  

Keywords:  blood pressure; cardiovascular diseases; hypertension; renal insufficiency, chronic; risk factors

Year:  2020        PMID: 33131314      PMCID: PMC7831968          DOI: 10.1161/HYPERTENSIONAHA.120.16155

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  46 in total

1.  Statistical analysis of correlated data using generalized estimating equations: an orientation.

Authors:  James A Hanley; Abdissa Negassa; Michael D deB Edwardes; Janet E Forrester
Journal:  Am J Epidemiol       Date:  2003-02-15       Impact factor: 4.897

2.  US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008.

Authors:  Brent M Egan; Yumin Zhao; R Neal Axon
Journal:  JAMA       Date:  2010-05-26       Impact factor: 56.272

3.  Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Authors:  Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

4.  Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system.

Authors:  John J Sim; Simran K Bhandari; Jiaxiao Shi; In Lu A Liu; David A Calhoun; Elizabeth A McGlynn; Kamyar Kalantar-Zadeh; Steven J Jacobsen
Journal:  Mayo Clin Proc       Date:  2013-10       Impact factor: 7.616

Review 5.  High blood pressure: the leading global burden of disease risk factor and the need for worldwide prevention programs.

Authors:  Samantha Bromfield; Paul Muntner
Journal:  Curr Hypertens Rep       Date:  2013-06       Impact factor: 5.369

6.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Authors:  Sarah Lewington; Robert Clarke; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

7.  Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial.

Authors:  O R Benavente; C S Coffey; R Conwit; R G Hart; L A McClure; L A Pearce; P E Pergola; J M Szychowski
Journal:  Lancet       Date:  2013-05-29       Impact factor: 79.321

8.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

9.  Chronic Kidney Disease Classification in Systolic Blood Pressure Intervention Trial: Comparison Using Modification of Diet in Renal Disease and CKD-Epidemiology Collaboration Definitions.

Authors:  Michael V Rocco; Arlene Chapman; Glenn M Chertow; Debbie Cohen; Jing Chen; Jeffrey A Cutler; Matthew J Diamond; Barry I Freedman; Amret Hawfield; Eric Judd; Anthony A Killeen; Kent Kirchner; Cora E Lewis; Nicholas M Pajewski; Barry M Wall; Jerry Yee
Journal:  Am J Nephrol       Date:  2016-08-12       Impact factor: 3.754

Review 10.  Hypertension in the aged: a pathophysiologic basis for treatment.

Authors:  M A Weber; J M Neutel; D G Cheung
Journal:  Am J Cardiol       Date:  1989-05-02       Impact factor: 2.778

View more
  1 in total

Review 1.  Tight Blood Pressure Control in Chronic Kidney Disease.

Authors:  Giorgio Gentile; Kathryn Mckinney; Gianpaolo Reboldi
Journal:  J Cardiovasc Dev Dis       Date:  2022-04-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.